Endoscopy plays a significant role in the diagnosis, management, and surveillance of colorectal cancer (CRC) and inflammatory bowel diseases (IBDs). Moreover, magnifying endoscopy and image-enhanced endoscopy has a crucial role in the clinical setting. Recently, a super-magnifying endoscope has been developed, and two devices, confocal laser endomicroscopy (CLE) and an endocytoscopy system (ECS), which allow in vivo microscopic inspection of the microstructural mucosal features of the gastrointestinal tract, are currently available. Studies on the use of ECS in CRC were reported by a Japanese group. Additionally, a few studies on the use of ECS in IBD have been reported. CLE has been shown to be reliable in assessing the activity of the disease in IBDs in both ulcerative colitis and Crohn's disease. Various published studies evaluated the use of CLE during colonoscopy to distinguish colorectal polyp pathology and neoplasia. However, these studies are heterogeneous, and further evidence is necessary to confirm the efficacy of CLE. Clin Endosc 2016;49:37-40
INTRODUCTION
Endoscopy plays a significant role in the diagnosis, management, and surveillance of colorectal cancer (CRC) and inflammatory bowel diseases (IBDs). Moreover, magnifying endoscopy 1,2 and image-enhanced endoscopy 3 have a crucial role in the clinical setting. Recently, a super-magnifying endoscope has been developed, and two devices, confocal laser endomicroscopy (CLE; Mauna Kea Technologies, Paris, France; and Pentax, Tokyo, Japan) and an endocytoscopy system (ECS; Olympus, Tokyo, Japan), which allow in vivo microscopic observation of the microstructural mucosa of the gastrointestinal tract, are currently available. These devices are used in clinical studies rather than in clinical practice. In this review article, we focused on the application and efficacy of these newly developed devices in the lower intestinal tract.
ENDOCYTOSCOPY
ECS is based on the principle of contact light microscopy. ECS observation also requires pretreatment with methylene blue or toluidine blue staining. 4 ECS has two types of endoscope: a probe-based ECS and an integrated scope-type ECS (iECS). The iECS has adjustable scope hardness with an outside diameter of 13.6 mm at the distal end and a working length of 1330 mm. 5 The first-generation iECS has a dual-charged coupled device (CCD, prototype, XCF-260EC1; Olympus). This scope can perform conventional and super-magnifying endoscopic observation consecutively using one-touch switch operation without changing the endoscope. In the ECS mode, this scope has a magnification capability of ×450, with a depth of field if 50 μm and a field of view of 400×400 μm. The second-generation iECS is a single-CCD integrated type (prototype, CF-Y0020-I; Olympus). It has a ×380 magnification, with a focusing depth of 50 μm and a field of view of 700×600 μm, which can obtain super-magnification with narrow band imaging (NBI) pictures.
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APPLICATION OF ENDOCYTOSCOPY SYSTEM FOR COLORECTAL CANCER
Several studies on the application of ECS in CRC were reported by a Japanese group. Kudo et al. 5 created an endocytoscopic (EC) classification for colonic neoplasia using iECS. They classified the normal mucosa as EC1a, all hyperplastic polyps as EC1b, dysplasias as EC2, and massively invasive submucosal cancers (SMm) or worse as EC3b. In that pilot study, they showed a sensitivity of 100% and a specificity of 100% (p<0.05) in differentiating nonneoplastic from neoplastic lesions. They also showed a high sensitivity (90.1%) and a high specificity (99.2%) in differentiating "SMm or worse" from other neoplastic lesions. Mori et al. 7 validated the EC classification using a randomized, controlled, open-label trial to determine the noninferiority of the first-generation iECS to standard biopsy. They showed that the diagnostic accuracy of iECS for the discrimination of neoplastic lesions was 94.1% (95% confidence interval [CI], 87.6 to 97.8), whereas that of standard biopsy was 96.0% (95% CI, 90.2 to 98.9). These results were within the noninferiority margin (absolute difference, −1.9%; 8.6% to 5.0%). They concluded that iECS was noninferior to standard biopsy in discriminating neoplastic lesions. In a recent study, Kudo et al. 8 focused on the microvasculature of colonic neoplasia. They evaluated 198 consecutive colonic lesions using second-generation iECS with NBI. They classified the EC vascular (EC-V) pattern into three categories: EC-V1, obscure surface microvessels; EC-V2, clearly observed surface microvessels of a uniform caliber and arrangement; EC-V3, dilated surface microvessels of nonhomogeneous caliber or arrangement. They showed that the sensitivity, specificity, and accuracy of the EC-V1 pattern for diagnosing hyperplastic polyps were 95.5%, 99.4%, and 99.0%, respectively, whereas those of the EC-V3 pattern for diagnosing invasive cancer were 74.6%, 97.2%, and 88.6%, respectively. They concluded that iECS could evaluate the microvasculature of colorectal lesions, and the EC-V pattern diagnosis was highly correlated with the histopathological diagnoses of other optical biopsy modalities.
APPLICATION OF ENDOCYTOSCOPY SYSTEM FOR INFLAMMATORY BOWEL DISEASE
A few studies concerning the use of ECS in IBDs have been reported. The efficacy of ECS in evaluating colonic inflammation has not yet been confirmed. We used ECS to diagnose amoebic colitis, an infectious type of colitis, in five patients. 9 We directly detected Entamoeba histolytica trophozoites in all five cases (100%). In contrast, serology only detected three patients (60%) positive for the disease, and hematoxylin and eosin staining showed three positive histological findings as well. We also applied ECS to ulcerative colitis (UC). We created an ECS score (ECSS) to determine the histopathological activity index of UC. 10 We used first-generation iECS with ×450 magnification, and sample biopsies were obtained from the same site. To validate the ECSS, we calculated the correlation between the ECSS and Matts' histopathological grade, which was determined by an expert pathologist. The ECSS of UC consists of the sum of the indices for shape (0 to 3), the distance between crypts (0 to 2), and the visibility of superficial microvessels (0 to 1). ECSS scores showed a strong correlation with Matts' histopathological grades (ρ=0.713, p<0.001).
Recently, another group 11 evaluated the clinical usefulness of ECSS in accurately monitoring UC during remission. They classified enrolled patients into two groups: those with an ECSS of 0 to 2 (grade A) and those with an ECSS of 3 to 6 (grade B). They reported that the relapse rate of grade B was significantly greater than that of grade A. They concluded that the ECSS might be a predictive indicator of UC relapse.
CONFOCAL LASER ENDOMICROSCOPY
CLE was first reported in 2004. Recently, it can be performed with two devices: one integrated into the endoscope (iCLE; Pentax) and another using a mini-probe through the scope (pCLE, Cellvizio; Mauna Kea Technologies) (Fig. 1) . 12 The pCLE consists of a laser scanning unit (Fig. 1A) and a mini-probe (Fig. 1B) . The mini-probe can be advanced through the working channel of a standard endoscope. CLE is based on tissue illumination with a low-power laser, with subsequent detection of the fluorescence of light reflected from the tissue. Confocal imaging can be based on tissue reflectance or fluorescence. Fluorescent contrast agents are most commonly used. Fluorescein sodium (fluorescein sodium, AK Fluor; Akorn Pharmaceutical, Lake Forest, IL, USA) is intravenously administered for CLE observation, 13 or acriflavine (Sigma Pharmaceuticals, Rowville, Australia), tetracycline, or cresyl violet (AnaSpec Inc., San Jose, CA, USA) are topically sprayed.
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APPLICATION OF CONFOCAL LASER ENDOMICROSCOPY FOR COLORECTAL CANCER AND POLYP
Various published studies evaluated the use of CLE during colonoscopy to distinguish colorectal polyp pathology and neoplasia (Table 1) . [15] [16] [17] [18] [19] [20] [21] [22] [23] However, these studies are heterogeneous. The sensitivity of CLE in distinguishing colorectal polyp pathology ranges from 43.4% to 100%. These studies are difficult to compare because of differing primary objectives and modality of CLE used (iCLE vs. pCLE). We need more evidence to be confirm the efficacy of CLE.
APPLICATION OF CONFOCAL LASER ENDOMICROSCOPY FOR INFLAMMATORY BOWEL DISEASE
CLE has been shown to assess the activity of the disease reliably in IBD, 24 both in UC and Crohn' s disease. Neumann et al. 25 developed a score named the Crohn' s Disease Endomicroscopic Activity Score (CDEAS) to assess in vivo real-time disease activity. CDEAS consists of six parameters: crypt number (increased or decreased), crypt distortion, microerosions, cellular infiltrate, vascularity, and number of goblet cells (increased or decreased). By assigning 1 point for each given parameter, the score ranges from 0 to 8. They showed that CDEAS strongly correlated with the C-reactive protein level. Li et al. 26 assessed the potential of CLE in the grading of UC activity. They focused on three categories: crypt architecture, microvascular alterations, and fluorescein leakage. They clas- 
FUTURE PERSPECTIVE
Super-magnifying endoscopy, including ECS and CLE, is mainly used in upper and lower intestinal diseases. Residual feces and/or mucous sometimes disturb optimal super-magnifying observation, and with the presence of a small amount of feces and mucus in the small intestine, the small intestinal circumference is appropriate for super-magnifying observation. We have started a pilot study using single-balloon enteroscopy and CLE to observe small intestinal diseases. In the near future, the use of super-magnifying endoscopy would be reported.
CONCLUSIONS
Super-magnifying endoscopy, including ECS and CLE, has the potential ability to obtain real-time in vivo histopathology.
